Clinical trial
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic…
NCT02257528 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT02257528 |
|---|---|
| Title | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer |
| Official title | A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | NRG Oncology |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7 |
| Intervention type | Biological, Other |
| Interventions | Laboratory Biomarker Analysis, Nivolumab |
| Enrollment | 26 |
| Start date | May 18, 2015 |
| Primary completion | Mar 5, 2019 |
| Completion | Mar 17, 2026 |
| First posted | Oct 6, 2014 |
| Last update posted | Sep 8, 2025 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: